Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2020

View Archived Issues

Ketamine and opioids

Link between lipid metabolism, cancer stem cell death and anti-tumor immunity mediated by ARF1

IGF1R inhibitors may find utility as head and neck squamous-cell carcinoma treatments

Noxafil approved in Japan for deep fungal infections

Dotinurad receives Japanese approval for hyperuricemia

AbbVie receives approval for Rinvoq in Japan

Thyradin S.I.V. Injection approved in Japan for myxedema coma and hypothyroidism

Virogin Biotech receives approval to initiate phase I study of VG-161 in Australia

AGTC reports interim data from ongoing phase I/II studies in achromatopsia

KEA-1010 retains analgesic and sedative potency in vivo

Results presented from phase III PENUT study of erythropoietin in preterm infants

Dayvigo approved in Japan for the treatment of insomnia

IFM Due discloses hSTING receptor antagonists

Shanghai Institute of Materia Medica patents GPR84 antagonists

Janssen Pharmaceutica NV patents prostanoid EP3 receptor antagonists

Daiichi Sankyo identifies new EGFR and/or HER2 mutant inhibitors

Metrion Biosciences describes new KCNA3 channel blockers

Study casts light on tumor initiating cells in breast cancer

Norbinaltorphimine shown efficacious for preclinical autism and ADHD

FDA grants accelerated approval of Tazverik for epithelioid sarcoma

Japanese approval for Corectim ointment for atopic dermatitis

Anerem approved in Japan for general anesthesia

BlackThorn initiates phase II proof-of-concept trial with BTRX-140 in major depressive disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...